University of Kentucky, College of Pharmacy, Department of Pharmaceutical Sciences - Drug Development Division, Lexington, KY 40536-0596, USA.
Eur J Pharm Sci. 2013 Jul 16;49(4):699-711. doi: 10.1016/j.ejps.2013.05.012. Epub 2013 May 23.
Pulmonary inhalation chemotherapeutic drug delivery offers many advantages for lung cancer patients in comparison to conventional systemic chemotherapy. Inhalable particles are advantageous in their ability to deliver drug deep in the lung by utilizing optimally sized particles and higher local drug dose delivery. In this work, spray-dried and co-spray dried inhalable lung surfactant-mimic PEGylated lipopolymers as microparticulate/nanoparticulate dry powders containing paclitaxel were rationally designed via organic solution advanced spray drying (no water) in closed-mode from dilute concentration feed solution. Dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) with varying PEG chain length were mixed with varying amounts of paclitaxel in methanol to produce co-spray dried microparticles and nanoparticles. Scanning electron microscopy showed the spherical particle morphology of the inhalable particles. Thermal analysis and X-ray powder diffraction confirmed the retention of the phospholipid bilayer structure in the solid-state following spray drying, the degree of solid-state molecular order, and solid-state phase transition behavior. The residual water content of the particles was very low as quantified analytically Karl Fisher titration. The amount of paclitaxel loaded into the particles was quantified which indicated high encapsulation efficiencies (43-99%). Dry powder aerosol dispersion performance was measured in vitro using the Next Generation Impactor (NGI) coupled with the Handihaler dry powder inhaler device and showed mass median aerodynamic diameters in the range of 3.4-7 μm. These results demonstrate that this novel microparticulate/nanoparticulate chemotherapeutic PEGylated phospholipid dry powder inhalation aerosol platform has great potential in lung cancer drug delivery.
与传统的全身化疗相比,肺部吸入化疗药物输送为肺癌患者提供了许多优势。吸入性颗粒具有将药物输送到肺部深处的优势,因为它们能够利用最佳大小的颗粒和更高的局部药物剂量输送。在这项工作中,通过有机溶液先进喷雾干燥(无水)在封闭模式下,从稀浓度进料溶液中合理设计了喷雾干燥和共喷雾干燥的肺表面活性剂模拟 PEG 化脂蛋白作为含有紫杉醇的微粒/纳米颗粒干粉。二棕榈酰磷脂酰胆碱(DPPC)和二棕榈酰磷脂酰乙醇胺聚(乙二醇)(DPPE-PEG)与不同长度的 PEG 链混合,在甲醇中与不同量的紫杉醇一起产生共喷雾干燥的微粒和纳米颗粒。扫描电子显微镜显示了可吸入颗粒的球形颗粒形态。热分析和 X 射线粉末衍射证实了喷雾干燥后磷脂双层结构在固态中的保留、固态分子有序度和固态相变行为。通过卡尔费休滴定法分析定量,颗粒中的残留水分含量非常低。定量测定了紫杉醇的载药量,表明包封效率高(43-99%)。使用下一代撞击器(NGI)与 Handihaler 干粉吸入器装置体外测量干粉气溶胶分散性能,显示质量中值空气动力学直径在 3.4-7 μm 范围内。这些结果表明,这种新型微粒/纳米化疗 PEG 化磷脂干粉吸入气溶胶平台在肺癌药物输送方面具有很大的潜力。